Background Agonists of the glucagon-like peptide-1 (GLP-1) receptor provide
pharmacological levels of GLP-1 activity, whereas dipeptidyl peptidase-4 (DPP-4) inhibitors …

Aim: The aim of this study was to compare the efficacy and safety of once‐daily human
glucagon‐like peptide‐1 analogue liraglutide with dipeptidyl peptidase‐4 inhibitor …

Background New treatments for type 2 diabetes mellitus are needed to retain insulin–
glucose coupling and lower the risk of weight gain and hypoglycaemia. We aimed to …

Aims/hypothesis The aim of the study was to compare the efficacy and safety of liraglutide in
type 2 diabetes mellitus vs placebo and insulin glargine (A21Gly, B31Arg, B32Arg human …

Aims To investigate efficacy and safety of dual therapy with liraglutide and metformin in
comparison to glimepiride and metformin, and metformin monotherapy over 2 years in …

Aim To confirm the superiority, compared with placebo, of adding liraglutide to pre‐existing
basal insulin analogue±metformin in adults with inadequately controlled type 2 diabetes …

OBJECTIVE—The efficacy and safety of adding liraglutide (a glucagon-like peptide-1
receptor agonist) to metformin were compared with addition of placebo or glimepiride to …

OBJECTIVE To assess the efficacy and safety of switching from sitagliptin to liraglutide in
metformin-treated adults with type 2 diabetes. RESEARCH DESIGN AND METHODS In an …

Background Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor
agonists, improve glycaemic control and reduce weight in patients with type 2 diabetes. In a …

Background Unlike most antihyperglycaemic drugs, glucagon-like peptide-1 (GLP-1)
receptor agonists have a glucose-dependent action and promote weight loss. We compared …